Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2012, Article ID 545492, 6 pages
http://dx.doi.org/10.1155/2012/545492
Case Report

Long-Term Survival after Gamma Knife Radiosurgery in a Case of Recurrent Glioblastoma Multiforme: A Case Report and Review of the Literature

1Gamma Knife of Spokane, Deaconess Health and Education Building, 910 W 5th Avenue, Suite 102, Spokane, WA 99204, USA
2Cancer Care Northwest, 910 W 5th Avenue, Suite 102, Spokane, WA 99204, USA
3MacKay & Meyer MDs, 711 S Cowley Street, Suite 210, Spokane, WA 99202, USA
4Spokane Brain & Spine, 801 W 5th Avenue, Suite 210, Spokane, WA 99204, USA

Received 22 December 2011; Accepted 15 January 2012

Academic Editor: Edward V. Craig

Copyright © 2012 Sudheer R. Thumma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Deorah, C. F. Lynch, Z. A. Sibenaller, and T. C. Ryken, “Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001,” Neurosurgical Focus, vol. 20, no. 4, article E1, 2006. View at Google Scholar · View at Scopus
  2. K. R. Hess, K. R. Broglio, and M. L. Bondy, “Adult glioma incidence trends in the United States, 1977–2000,” Cancer, vol. 101, no. 10, pp. 2293–2299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. P. Polednak and J. T. Flannery, “Brain, other central nervous system, and eye cancer,” Cancer, vol. 75, no. 1, pp. 330–337, 1995. View at Google Scholar · View at Scopus
  4. M. Salcman, R. S. Kaplan, G. M. Samaras et al., “Aggressive multimodality therapy based on a multicompartmental model of glioblastoma,” Surgery, vol. 92, no. 2, pp. 250–259, 1982. View at Google Scholar · View at Scopus
  5. J. Gerstein, K. Franz, J. P. Steinbach et al., “Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma,” Radiotherapy and Oncology, vol. 97, no. 3, pp. 382–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. H. G. Hollerhage, M. Zumkeller, M. Becker, and H. Dietz, “Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme,” Acta Neurochirurgica, vol. 113, no. 1-2, pp. 31–37, 1991. View at Google Scholar · View at Scopus
  7. M. L. Affronti, C. R. Heery, J. E. Herndon II et al., “Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy,” Cancer, vol. 115, no. 15, pp. 3501–3511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Ashby, R. LaRocca, and T. Ryken, “Treatment of brain tumors,” New England Journal of Medicine, vol. 352, no. 22, pp. 2350–2353, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. K. A. Smith, L. S. Ashby, F. Gonzalez et al., “Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme,” Journal of Neurosurgery, vol. 109, pp. 106–117, 2008. View at Google Scholar · View at Scopus
  10. S. B. Tatter, “Recurrent malignant glioma in adults,” Current Treatment Options in Oncology, vol. 3, no. 6, pp. 509–524, 2002. View at Google Scholar · View at Scopus
  11. H. S. Friedman, M. D. Prados, P. Y. Wen et al., “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4733–4740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Brandes, “State-of-the-art treatment of high-grade brain tumors,” Seminars in Oncology, vol. 30, supplement 19, no. 6, pp. 4–9, 2003. View at Google Scholar
  13. E. Fokas, U. Wacker, M. W. Gross, M. Henzel, E. Encheva, and R. Engenhart-Cabillic, “Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?” Strahlentherapie und Onkologie, vol. 185, no. 4, pp. 235–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Gabayan, S. B. Green, A. Sanan et al., “GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis,” Neurosurgery, vol. 58, no. 4, pp. 701–709, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Minniti, V. Armosini, M. Salvati et al., “Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma,” Journal of Neurooncology, vol. 103, no. 3, pp. 689–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Patel, F. Siddiqui, J. Y. Jin et al., “Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival,” Journal of Neurooncology, vol. 92, no. 2, pp. 185–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. H. Cho, W. A. Hall, B. J. Gerbi, P. D. Higgins, W. A. McGuire, and H. B. Clark, “Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas,” International Journal of Radiation Oncology Biology Physics, vol. 45, no. 5, pp. 1133–1141, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. K. H. Cho, W. A. Hall, S. S. Lo, and K. E. Dusenbery, “Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme,” Technology in Cancer Research and Treatment, vol. 3, no. 1, pp. 41–49, 2004. View at Google Scholar · View at Scopus
  19. S. E. Combs, C. Thilmann, L. Edler, J. Debus, and D. Schulz-Ertner, “Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8863–8869, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. E. Combs, V. Widmer, C. Thilmann, H. Hof, J. Debus, and D. Schulz-Ertner, “Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM),” Cancer, vol. 104, no. 10, pp. 2168–2173, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. K. Park, T. Hodges, L. Arko et al., “Scale to predict survival after surgery for recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 28, no. 24, pp. 3838–3843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Phuphanich, S. Ferrall, and H. Greenberg, “Long-term survival in malignant glioma. Prognostic factors,” Journal of the Florida Medical Association, vol. 80, no. 3, pp. 181–184, 1993. View at Google Scholar · View at Scopus
  23. M. Glas, C. Happold, J. Rieger et al., “Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1257–1261, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. J. Layfield, C. Willmore, S. Tripp, C. Jones, and R. L. Jensen, “Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors,” Applied Immunohistochemistry and Molecular Morphology, vol. 14, no. 1, pp. 91–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. S. R. Tripp, C. Willmore-Payne, and L. J. Layfield, “Relationship between EGFR overexpression and gene amplification status in central nervous system gliomas,” Analytical and Quantitative Cytology and Histology, vol. 27, no. 2, pp. 71–78, 2005. View at Google Scholar
  26. F. E. Bleeker, N. A. Atai, S. Lamba et al., “The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma,” Acta Neuropathologica, vol. 119, no. 4, pp. 487–494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Boldrini, S. Pistolesi, S. Gisfredi et al., “Telomerase activity and hTERT mRNA expression in glial tumors,” International Journal of Oncology, vol. 28, no. 6, pp. 1555–1560, 2006. View at Google Scholar · View at Scopus
  28. V. Donato, A. Papaleo, A. Castrichino et al., “Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide,” Tumori, vol. 93, no. 3, pp. 248–256, 2007. View at Google Scholar · View at Scopus
  29. S. Umesh, A. Tandon, V. Santosh et al., “Clinical and immunohistochemical prognostic factors in adult glioblastoma patients,” Clinical Neuropathology, vol. 28, no. 5, pp. 362–372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. C. Quant, J. Drappatz, P. Y. Wen, and A. D. Norden, “Recurrent high-grade glioma,” Current Treatment Options in Neurology, vol. 12, no. 4, pp. 321–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Schmidt, J. Fischer, U. Herrlinger, K. Dietz, J. Dichgans, and M. Weller, “PCV chemotherapy for recurrent glioblastoma,” Neurology, vol. 66, no. 4, pp. 587–589, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. M. C. Chamberlain, “Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme,” Journal of Neurooncology, vol. 56, no. 2, pp. 183–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Minniti, R. Muni, G. Lanzetta, P. Marchetti, and R. Maurizi Enrici, “Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents,” Anticancer Research, vol. 29, no. 12, pp. 5171–5184, 2009. View at Google Scholar · View at Scopus
  34. R. Stupp, M. E. Hegi, M. J. van den Bent et al., “Changing paradigms—an update on the multidisciplinary management of malignant glioma,” Oncologist, vol. 11, no. 2, pp. 165–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Trent, A. Kong, S. C. Short et al., “Temozolomide as second-line chemotherapy for relapsed gliomas,” Journal of Neurooncology, vol. 57, no. 3, pp. 247–251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Galanis, J. C. Buckner, M. J. Maurer et al., “Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5294–5304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. D. M. Peereboom, D. R. Shepard, M. S. Ahluwalia et al., “Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme,” Journal of Neurooncology, vol. 98, no. 1, pp. 93–99, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. J. Study, “HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme,” Journal of Neurooncology, vol. 74, no. 1, pp. 77–86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Terasaki, S. Shibui, Y. Narita et al., “Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme,” Journal of Clinical Oncology, vol. 29, no. 3, pp. 337–344, 2011. View at Publisher · View at Google Scholar
  40. G. A. Moviglia, A. G. Carrizo, G. Varela et al., “Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme,” Hematology/Oncology and Stem Cell Therapy, vol. 1, no. 1, pp. 3–13, 2008. View at Google Scholar · View at Scopus
  41. K. Chino, D. Silvain, A. Grace, J. Stubbs, and B. Stea, “Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite radiation therapy system,” Medical Physics, vol. 35, no. 7, pp. 3383–3388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. C. Chamberlain, D. Barba, P. Kormanik, and W. M. C. Shea, “Stereotactic radiosurgery for recurrent gliomas,” Cancer, vol. 74, no. 4, pp. 1342–1347, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Souhami, W. Seiferheld, D. Brachman et al., “Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol,” International Journal of Radiation Oncology Biology Physics, vol. 60, no. 3, pp. 853–860, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. A. T. Villavicencio, S. Burneikiene, P. Romanelli et al., “Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience,” Neurosurgical Review, vol. 32, no. 4, pp. 417–424, 2009. View at Publisher · View at Google Scholar · View at Scopus